FDA Ends Enforcement Discretion on Biologics and Regenerative Products

S. Raymond Golish, MD, PhD, MBA, FAAOS; Ryan Pezold, MA; David S. Jevsevar, MD, MBA, FAAOS

The FDA has formally ended the “enforcement discretion” of its comprehensive policy framework on biologics and regenerative medicine products.

New CPG and AUC Offer Guidance on More than 24 Perioperative Pain Management Interventions

Terry Stanton

In July, the Board of Directors approved a Clinical Practice Guideline (CPG) and an accompanying set of Appropriate Use Criteria (AUC) on Pharmacologic, Physical, and Cognitive Pain Alleviation for Musculoskeletal Extremity/Pelvis Surgery.